← LISATA THERAPEUTICS, INC. (LSTA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
LISATA THERAPEUTICS, INC. (LSTA)
Pharmaceutical Preparations · market cap $13M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
11
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Lisata Therapeutics (LSTA) is a clinical-stage oncology and cardiovascular biopharmaceutical company formed via the 2022 merger of Cend Therapeutics and Caladrius Biosciences, with a market cap of approximately $34M and 26 employees. Its lead asset is autologous CD34+ cell therapy in Phase 3 for Chronic Myocardial Ischemia, supported by a broad but cash-intensive pipeline spanning cardiovascular indications, melanoma, cholangiocarcinoma, and diabetes. With $13.1M in cash and a runway of roughly 12.7 months, the company faces an acute financing overhang.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CLBS12 | Phase 2 | Critical Limb Ischemia |
| therapeutic autologous dendritic cells | Phase 2 | Melanoma (Skin) |
| CLBS16 | Phase 2 | Coronary Microvascular Dysfunction |
| Auto-CD34+ cells | Phase 3 | Chronic Myocardial Ischemia |
| NBS10 | Phase 2 | ST Segment Elevation Myocardial Infarction |
| CLBS14 (low-dose) | Phase 2 | Myocardial Ischemia |
| CLBS03 Low Dose | Phase 2 | Diabetes Mellitus |
| certepetide | Phase 2 | Cholangiocarcinoma |
| CLBS03 High Dose | Phase 2 | Diabetes Mellitus |
| CLBS14 (high-dose) | Phase 2 | Myocardial Ischemia |
| SOC | Phase 2 | Critical Limb Ischemia |
Price & technical context
3-month
-8.6%
6-month
-66.0%
12-month
-54.9%
52-wk range
$0.99–$5.04
vs 50-day MA
-24.3%
vs 200-day MA
-64.8%
Realized vol
117.6%
Max drawdown
-80.4%
Daily closes through 2026-10-26. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LSTA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.